Krka d. d (KRK) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.062x

Based on the latest financial reports, Krka d. d (KRK) has a cash flow conversion efficiency ratio of 0.062x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł146.54 Million ≈ $40.33 Million USD) by net assets (zł2.38 Billion ≈ $654.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See KRK defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Krka d. d - Cash Flow Conversion Efficiency Trend (2010–2025)

This chart illustrates how Krka d. d's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Krka d. d Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Krka d. d ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
SKANSKA AB (SPONS.ADR)/1
F:SKN
0.064x
China Zheshang Bank Co Ltd
SHG:601916
-0.430x
Macronix International Co Ltd
TW:2337
0.045x
Autoliv Inc
ST:ALIV-SDB
-0.028x
LPP S.A.
WAR:LPP
0.432x
GameStop Corp.
NYSE:GME
0.036x
Weichai Power Co. Ltd
F:WI4
0.057x
Hindustan Petroleum Corporation Limited
NSE:HINDPETRO
0.336x

Annual Cash Flow Conversion Efficiency for Krka d. d (2010–2025)

The table below shows the annual cash flow conversion efficiency of Krka d. d from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see KRK company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 zł2.38 Billion
≈ $654.23 Million
zł528.62 Million
≈ $145.48 Million
0.222x +37.87%
2024-12-31 zł2.24 Billion
≈ $615.87 Million
zł360.93 Million
≈ $99.33 Million
0.161x +54.85%
2023-12-31 zł2.18 Billion
≈ $600.45 Million
zł227.25 Million
≈ $62.54 Million
0.104x -52.37%
2022-12-31 zł2.14 Billion
≈ $588.55 Million
zł467.65 Million
≈ $128.70 Million
0.219x +8.69%
2021-12-31 zł1.92 Billion
≈ $528.16 Million
zł386.10 Million
≈ $106.26 Million
0.201x -2.30%
2020-12-31 zł1.75 Billion
≈ $482.12 Million
zł360.76 Million
≈ $99.29 Million
0.206x -1.75%
2019-12-31 zł1.67 Billion
≈ $458.92 Million
zł349.52 Million
≈ $96.19 Million
0.210x +11.35%
2018-12-31 zł1.54 Billion
≈ $423.90 Million
zł289.95 Million
≈ $79.80 Million
0.188x +22.92%
2017-12-31 zł1.49 Billion
≈ $409.44 Million
zł227.83 Million
≈ $62.70 Million
0.153x +3.61%
2016-12-31 zł1.44 Billion
≈ $397.53 Million
zł213.49 Million
≈ $58.76 Million
0.148x -25.23%
2015-12-31 zł1.41 Billion
≈ $386.95 Million
zł277.94 Million
≈ $76.49 Million
0.198x +56.41%
2014-12-31 zł1.35 Billion
≈ $372.06 Million
zł170.87 Million
≈ $47.03 Million
0.126x -44.37%
2013-12-31 zł1.33 Billion
≈ $366.75 Million
zł302.75 Million
≈ $83.32 Million
0.227x +1.26%
2012-12-31 zł1.24 Billion
≈ $341.41 Million
zł278.33 Million
≈ $76.60 Million
0.224x +3.51%
2011-12-31 zł1.14 Billion
≈ $313.68 Million
zł247.06 Million
≈ $67.99 Million
0.217x +25.79%
2010-12-31 zł1.05 Billion
≈ $289.89 Million
zł181.52 Million
≈ $49.96 Million
0.172x --

About Krka d. d

WAR:KRK Poland Drug Manufacturers - Specialty & Generic
Market Cap
$9.43 Billion
zł34.25 Billion PLN
Market Cap Rank
#2359 Global
#11 in Poland
Share Price
zł1130.00
Change (1 day)
-0.18%
52-Week Range
zł806.00 - zł1148.00
All Time High
zł1148.00
About

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, an… Read more